Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662519 · ClinicalTrials.gov registry record · Phase 1
Neulasta in Type 1 Diabetes
A Phase 1 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00662519 is a Phase 1 study that has completed, run by University of Florida. The registered enrollment target is 21 participants.
The verdict
NCT00662519, a Phase 1 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The primary purpose of this study is to find out if giving a 12 week course of Neulasta (Pegylated granulocyte colony stimulating factor (GCSF)) to people with type 1 diabetes (T1D) is safe. The secondary purpose of this research study is to determin if giving GCSF to patients with T1D changes the immune system or preserves insulin production.
Interventions
- DRUG Placebo
- DRUG Neulasta (Pegylated)
- DIETARY_SUPPLEMENT Mixed Meal Tolerance Test (MMTT)
- OTHER Blood test
- OTHER DNA Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662519
The ClinicalTrials.gov registry entry for NCT00662519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00662519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662519 about?
NCT00662519 is a clinical study titled "Neulasta in Type 1 Diabetes". The primary purpose of this study is to find out if giving a 12 week course of Neulasta (Pegylated granulocyte colony stimulating factor (GCSF)) to people with type 1 diabetes (T1D) is safe. The secondary purpose of this research study is to determin if giving GCSF to patients with T1D changes the i...
What is the current status of trial NCT00662519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2008-04. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00662519?
The interventions under investigation include: Placebo (DRUG), Neulasta (Pegylated) (DRUG), Mixed Meal Tolerance Test (MMTT) (DIETARY_SUPPLEMENT), Blood test (OTHER), DNA Test (OTHER).
Who is sponsoring clinical trial NCT00662519?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.